Genmab partner gets approval for lung cancer drug from Duobody platform

Janssen Pharmaceuticals has received approval for lung cancer drug Rybrevant

Photo: Joost Melis / Genmab / PR

On Friday, Genmab's partner Janssen Pharmaceuticals has been granted approval to launch lung cancer drug Rybrevant from the US Food and Drug Administration (FDA).

The drug was developed via Genmab's Duobody platform making it the first product from this platform to receive regulatory approval.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs